Novosti

Povratak

FEBS Journal “Special Issue: COVID‐19, one year on”

FEBS Journal “Special Issue: COVID‐19, one year on”

Objavljeno 11.09.2021.

Časopis “FEBS Journal” objavio je specijalno izdanje “COVID‐19, one year on” posvećeno trenutno najistaknutijoj problematici u znanstvenom svijetu. Ovo izdanje donosi niz zanimljivih znanstvenih članaka o dosadašnjim spoznajama vezanim uz djelovanje, terapiju i razvoj cjepiva protiv virusa SARS-CoV-2.

Više možete pronaći na linku “Special Issue: COVID‐19, one year on”

Popis objavljenih članaka:

  1. Zacchigna S, Marcello A, Banks L (2021) Spotlight on COVID-19: eighteen months on. FEBS J. 288, 4992-4995.
  2. Dhillon P, Altmann D & Male V (2021) COVID-19 vaccines: what do we know so far? FEBS J. 288, 4996-5009.
  3. Seyran M, Takayama K, Uversky VN, Lundstrom K, Palù G, Sherchan SP, Attrish D, Rezaei N, Aljabali AAA, Ghosh S et al. (2020) The Structural Basis of Accelerated Host Cell Entry by SARS-CoV-2. FEBS J. 288, 5010-5020.
  4. Lin H, Ma X, Xiao F, Su H, Shi Y, Liu Y, Song L, Zhang Z, Zhang C & Peng H (2021) Identification of a special cell type as a determinant of the kidney tropism of SARS-CoV-2. FEBS J. 288, 5163-5178.
  5. Ku CL, Chen IT & Lai MZ (2021) Infection-induced inflammation from specific inborn errors of immunity to COVID-19. FEBS J. 288, 5021-5041.
  6. Tong ZWM, Grant E, Gras S, Wu M, Smith C, Barrett HL, Gallo LA &, Short KR (2021) The role of T-cell immunity in COVID-19 severity amongst people living with type II diabetes. FEBS J. 288, 5042-5054.
  7. Zeng HL, Chen D, Yan J, Yang Q, Han QQ, Li SS & Cheng L (2020) Proteomic characteristics of bronchoalveolar lavage fluid in critical COVID-19 patients. FEBS J. 288, 5190-5200.
  8. Chen CC, Yu X, Kuo CJ, Min J, Chen S, Ma L, Liu K & Guo RT (2021) Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases. FEBS J. 288, 5089-5121.
  9. Saramago M, Bárria C, Costa VG, Souza CS, Viegas SC, Domingues S, Lousa D, Soares CM, Arraiano CM & Matos RG (2021) New targets for drug design: importance of nsp14/nsp10 complex formation for the 3’-5’ exoribonucleolytic activity on SARS-CoV-2. FEBS J. 288, 5130-5147.
  10. Caillet-Saguy C, Durbesson F, Rezelj VV, Gogl G, Tran QD, Twizere JC, Vignuzzi M, Vincentelli R & Wolff N (2021) Host PDZ-containing proteins targeted by SARS-CoV-2. FEBS J. FEBS J. 288, 5148-5162.
  11. Prasad H (2021) Protons to patients: targeting endosomal Na+/H+ exchangers against COVID-19 and other viral diseases. FEBS J. 288, 5071-5098.
  12. Mok, D.Z.L., Chan, C.Y.Y., Ooi, E.E. and Chan, K.R. (2020) The effects of aging on host resistance and disease tolerance to SARS-CoV-2 infection. FEBS J. 288, 5055-5070.
  13. Merzon, E., Green, I., Vinker, S., Golan-Cohen, A., Gorohovski, A., Avramovich, E., Frenkel-Morgenstern, M. and Magen, E. (2021) The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection. FEBS J. 288, 5179-5189.